Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on November 24, 2014. The report details the entry into a Material Definitive Agreement on the same date with Austrianova Singapore Pte Ltd, a subsidiary partially owned by the Company.
Key Financial Metrics and Agreement Terms
The filing discloses specific financial obligations related to a Licensing Agreement for "Cell-in-a-Box" live cell encapsulation technology. The filing text does not provide general revenue, profit, cash flow, or debt metrics for the company.
- License Fee: Total initial fee of $2,000,000 due by June 30, 2015.
- Payments Made: $500,000 paid at signing; remaining balance to be paid in periodic monthly installments.
- Royalty Rates: 10% on direct sales; 20% on sales by a sub-licensee.
- Milestone Payments:
- $100,000: Within 30 days of first pre-clinical experiments.
- $500,000: Within 30 days of enrolling a human in the first clinical trial.
- $800,000: Within 30 days of enrolling a human in the first Phase 3 clinical trial.
- $1,000,000: Within 90 days of obtaining the first Marketing Authorization.
Material Changes and Outlook
The primary material change is the acquisition of an exclusive worldwide royalty-bearing license (with sublicense rights) to use genetically modified non-stem cells designed to activate Cannabinoids for research, development, and commercialization. The agreement is effective as of December 1, 2014. The filing does not provide specific forward-looking guidance, management commentary on financial outlook, or a discussion of risks beyond the contractual obligations.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the remaining $1.5 million initial license fee and future milestone payments.
- Confirm the regulatory status of the "Cell-in-a-Box" technology and the timeline for pre-clinical and clinical trials.
- Review the ownership structure of Austrianova Singapore Pte Ltd to understand the related-party nature of the transaction.
- Assess the commercial viability of treatments targeting Cannabinoid activation using non-stem cells.